AG
PVLA

Algert Global’s Palvella Therapeutics PVLA Stock Holding History

Algert Global’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-138
Closed -$25K – 516
2020
Q1 		$25K Hold
138
– – 0.01% 394
2019
Q4 		$40K Sell
138
-125
-48% -$34.7K 0.01% 365
2019
Q3 		$72K Buy
+263
New +$102K 0.03% 338
2018
Q2 		– Sell
-1,181
Closed -$644K – 391
2018
Q1 		$644K Buy
+1,181
New +$731K 0.12% 231

Other funds holding PVLA

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Algert Global's PVLA Position: Q2 2020 in Review

Algert Global sold out of Palvella Therapeutics (PVLA) in Q2 2020, closing a stake of 138 shares — an estimated $25K sold.

Algert Global first reported a position in PVLA in Q1 2018 and held it in 4 quarters. The position peaked at $644K in Q1 2018. 96 funds tracked by Wall St. Rank hold PVLA as of Q2 2020.

  • Algert Global reported no remaining Palvella Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Algert Global sold 138 Palvella Therapeutics shares in Q2 2020, an estimated $25K.
  • Algert Global first reported a position in Palvella Therapeutics in Q1 2018 and held it in 4 quarters.
  • Algert Global's Palvella Therapeutics position peaked at $644K in Q1 2018.
  • 96 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2020.

Based on Algert Global's 13F filing for Q2 2020, filed 12 Aug 2020.